Samsung SDS has unveiled its plans to test series of projects for blockchain-powered medicine distribution management this November. The tests are aimed at ensuring transparency of pharmaceutical products tracking.
Dubbed “Disruptive innovation technology for tracking drug distribution history,” the Samsung’s pilot programs were announced at the BioPharma Cold Chain Logistics session in Seoul, South Korea. The pilots will take up up to six months.
Samsung SDS officials told that they’ve already received applications for the pilots from “several” pharmaceutical firms in South Korea.
In case of success, the pilots will be commercialized after passing domestic and foreign regulatory compliance in June of next year.